ArticleClinical ophthalmology (Auckland, N.Z.)2011
Low-dose subconjunctival bevacizumab to augment trabeculectomy for glaucoma.
Article in Clinical ophthalmology (Auckland, N.Z.), 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 4 syntheses or guidelines pooled it, 29 citations in OpenAlex.
- Pooled it
- Pooled it
- Anti-vascular endothelial growth factor for control of wound healing in glaucoma surgery.The Cochrane database of systematic reviews · 2016Pooled it
- Anti-vascular endothelial growth factor for neovascular glaucoma.The Cochrane database of systematic reviews · 2013Pooled it
- Comparison of the effect of mitomycin C and bevacizumab-methylcellulose mixture on combined phacoemulsification and non-penetrating deep sclerectomy surgery on the intraocular pressure (a clinical trial study).International ophthalmology · 2019Trial
- Anti-vascular endothelial growth factor for neovascular glaucoma.The Cochrane database of systematic reviews · 2020Review
- Postoperative adjunctive bevacizumab versus placebo in primary trabeculectomy surgery for glaucoma.International journal of ophthalmology · 2019Article
- Short-Term Results of Sutureless Scleral Tunnel Trabeculectomy Using Adjunctive Topical Bevacizumab.Medical hypothesis, discovery & innovation ophthalmology journal · 2018Article
- Evaluation of topical bevacizumab as an adjunct to mitomycin C augmented trabeculectomy.Journal of current ophthalmology · 2017Article
- Improving patient outcomes following glaucoma surgery: state of the art and future perspectives.Clinical ophthalmology (Auckland, N.Z.) · 2014Review
- Subconjunctival bevacizumab to augment trabeculectomy with mitomycin C in the management of failed glaucoma surgery.Clinical ophthalmology (Auckland, N.Z.) · 2014Article
- Anti-VEGF Agents and Glaucoma Filtering Surgery.Journal of ophthalmic & vision research · 2013Article
- Revisiting corneal topography for the diagnosis of keratoconus: use of Rabinowitz's KISA% index.Clinical ophthalmology (Auckland, N.Z.) · 2012Article
- Outcome of penetrating keratoplasty in corneal ulcer: a single-center experience.Clinical ophthalmology (Auckland, N.Z.) · 2011Article
- Bevacizumab in Glaucoma: Where do We Stand?Journal of current glaucoma practiceReview
- The Anti-VEGF Epidemic: What are the Implications for Glaucoma Services?Journal of current glaucoma practiceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe purpose of this study was to assess the effect of bevacizumab in maintaining intraocular pressure lowered by trabeculectomy in refractory open-angle glaucoma.
methodsThirty-seven eyes from 37 patients referring to Nikoukari Ophthalmology University Hospital in Tabriz were enrolled in this randomized clinical trial. Seventeen patients were randomly assigned to receive bevacizumab augmentation after trabeculectomy, and 20 patients were assigned to a control group receiving a placebo injection of normal saline. Bevacizumab was injected subconjunctivally at a dose of 0.2 mg. Intraocular pressure was measured on eight occasions, ie, at baseline, 24 hours, 3 days, 7 days, 2 weeks, 1 month, 2 months, and 3 months after treatment.
resultsMen constituted 81% of the participants, who were of mean age 67.5 years. Twenty-nine patients had secondary open-angle glaucoma, while eight patients had primary open-angle glaucoma. Intraocular pressure decreased from a mean of 28.4 mmHg at baseline to a mean of 12.1 mmHg during the first day and to 15.1 mmHg after 3 months. Adding bevacizumab to trabeculectomy was not found to affect intraocular pressure differently to placebo. Neither the results of repeated measurements analysis nor single comparison statistical tests were significant for a difference in efficacy of bevacizumab versus placebo.
conclusionSubconjunctival bevacizumab 0.2 mg was not found to affect the trend in intraocular pressure more than placebo after trabeculectomy for open-angle glaucoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.